An autoantibody profile identified by human genome-wide protein arrays in rheumatoid arthritis
Xu Liu,Xiaoying Zhang,Yu-Jian Kang,Fei Huang,Shuang Liu,Yixue Guo,Yingni Li,Changcheng Yin,Mingling Liu,Qimao Han,Qingwen Wang,Hua Ye,Haihong Yao,Chun Li,Jiahe Li,Wangzha Pingcuo,Yan Zhang,Yin Su,Ge Gao,Zhanguo Li,Xiaolin Sun
DOI: https://doi.org/10.1002/mco2.679
2024-08-11
Abstract:Precise diagnostic biomarkers of anticitrullination protein antibody (ACPA)-negative and early-stage RA are still to be improved. We aimed to screen autoantibodies in ACPA-negative patients and evaluated their diagnostic performance. The human genome-wide protein arrays (HuProt arrays) were used to define specific autoantibodies from the sera of 182 RA patients and 261 disease and healthy controls. Statistical analysis was performed with SPSS 17.0. In Phase I study, 51 out of 19,275 recombinant proteins covering the whole human genome were selected. In Phase II validation study, anti-ANAPC15 (anaphase promoting complex subunit 15) exhibited 41.8% sensitivity and 91.5% specificity among total RA patients. There were five autoantibodies increased in ACPA-negative RA, including anti-ANAPC15, anti-LSP1, anti-APBB1, anti-parathymosin, and anti-UBL7. Anti-parathymosin showed the highest prevalence of 46.2% (p = 0.016) in ACPA-negative early stage (<2 years) RA. To further improve the diagnostic efficacy, a prediction model was constructed with 44 autoantibodies. With increased threshold for RA calling, the specificity of the model is 90.8%, while the sensitivity is 66.1% (87.8% in ACPA-positive RA and 23.8% in ACPA-negative RA) in independent testing patients. Therefore, HuProt arrays identified RA-associated autoantibodies that might become possible diagnostic markers, especially in early stage ACPA-negative RA.